Aimmune Therapeutics Inc (NASDAQ:AIMT) Director Kathryn E. Falberg acquired 30,000 shares of Aimmune Therapeutics stock in a transaction that occurred on Monday, February 26th. The stock was acquired at an average cost of $32.00 per share, with a total value of $960,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) opened at $31.67 on Wednesday. Aimmune Therapeutics Inc has a 52 week low of $15.97 and a 52 week high of $42.00. The stock has a market cap of $1,610.00 and a price-to-earnings ratio of -15.30.
Several equities research analysts recently issued reports on AIMT shares. Roth Capital lifted their price objective on shares of Aimmune Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Cantor Fitzgerald started coverage on shares of Aimmune Therapeutics in a research note on Tuesday, December 12th. They issued an “overweight” rating and a $55.00 price objective for the company. BidaskClub lowered shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 4th. Wedbush reaffirmed an “outperform” rating on shares of Aimmune Therapeutics in a research note on Monday, February 12th. Finally, Piper Jaffray Companies lifted their price objective on shares of Aimmune Therapeutics from $38.00 to $60.00 and gave the company an “overweight” rating in a research note on Tuesday, December 5th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $55.22.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.